Johannes Oldenburg

Professor, Chairman and Director
University Clinic Bonn AöR, Institute of Experimental Haematology and Transfusion Medicine, Bonn, Germany

Professor Oldenburg is a Director at the Institute of Experimental Haematology and Transfusion Medicine and at the Haemophilia Centre at the University Clinic in Bonn, Germany. His research interests include the molecular genetics of blood coagulation factors, specifically with haemophilia and vitamin K pathways with more than 500 peer reviewed publications in these fields. He is the recipient of the GTH Alexander Schmidt Award (2000) and the ISTH Biennial Investigator Recognition Award (2007). He served as President of the 26th ISTH Congress in 2017, and since 2019 he has been the President of GTH

Presentation(s):

• OC 07.1 - Role of GABARAP protein in the intracellular distribution of FVIII

  Saturday, July 9, 2022
  1:00 PM – 1:15 PM

• OC 07.3 - Whole genome expression analysis resolves the correlation between genetic knockout of single genes and the obtained phenotype in relation to FVIII secretion

  Saturday, July 9, 2022
  1:30 PM – 1:45 PM

• OC 07.4 - Exploring the conformational landscape of Factor VIII B domain in order to generate an all atom full length structure of the coagulation Factor VIII protein

  Saturday, July 9, 2022
  1:45 PM – 2:00 PM

• LB 01.3 - Relationship between transgene-produced FVIII and bleeding rates 2 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8-1

  Sunday, July 10, 2022
  3:15 PM – 3:30 PM

• LB 01.4 - Efficacy, Safety, and Pharmacokinetics of Once-Weekly Efanesoctocog Alfa (BIVV001) Prophylaxis in Previously Treated Patients With Severe Hemophilia A: Results From the Phase 3 XTEND-1 Study

  Sunday, July 10, 2022
  3:30 PM – 3:45 PM

• OC 27.4 - Recombinant factor VIII Fc showed better prophylactic effectiveness compared to standard half-life factor VIII in haemophilia A - results from A-SURE, a 24-month prospective, non-interventional study

  Sunday, July 10, 2022
  3:30 PM – 3:45 PM

• PB0008 - Neutralizing anti-emicizumab antibodies in a patient with Acquired Hemophilia A

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0179 - Establishment of a monolayer-based LSEC-like endothelial cell in vitro system from induced pluripotent stem cells

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0184 - FVIII-specific Immune Response in Hemophilia A Mice Upon Infection

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• OC 43.1 - Idntification of a von Willebrand factor homozygous deep intronic variant by next-generation analysis, and subsequent validation by mRNA analysis and study of the patient-derived endothelial cells

  Monday, July 11, 2022
  2:45 PM – 3:00 PM

• PB0540 - Investigation of GGCX interaction with VKD proteins

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0621 - Virtually screening for novel small molecule inhibitors against the conformational landscape of coagulation factor XIII activation-path

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0622 - Determining the dominant-negative causality of FXIII heterozygous mutations using a bi-cistronic, bi-tagged expression system

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0715 - Exploring diverse coagulation Factor XIII subunit expression datasets: A bioinformatic analysis

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0735 - Understanding fate of circulating von Willebrand factor following interaction with polymorphonuclear leukocytes

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• OC 67.2 - Personalized Assessment of the Protein C Pathway Using Endothelial Colony Forming Cells

  Tuesday, July 12, 2022
  3:00 PM – 3:15 PM

• PB1123 - Annualised Bleeding Rate and Joint Health: Second Interim Analysis of the Real-world HEM-POWR Study Evaluating the Effectiveness of Damoctocog Alfa Pegol in Patients With Haemophilia A

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1134 - Practical utilisation of Octapharma FVIII concentrates in previously untreated and minimally treated haemophilia A patients entering routine clinical treatment – The Protect-NOW Study

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1146 - Determinants of successful immune tolerance induction in persons with hemophilia A – systematic review and meta-analysis

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1309 - Study the role of endothelial protein C receptor gene polymorphisms in Indian DVT patients

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• OC 76.1 - Functional characterization and structural modeling of DNA-aptamers targeting activated coagulation Factor XIII

  Wednesday, July 13, 2022
  10:15 AM – 10:30 AM

• OC 78.5 - Exploring hidden bleeding phenotypes by screening FXIII and Fibrinogen genes

  Wednesday, July 13, 2022
  11:15 AM – 11:30 AM